Targeting BCL-2 in T-cell Leukemia:
We utilize state-of-the-art technology BH3 profiling to determine sensitivity to apoptosis and anti-apoptotic dependencies for discovering targeted therapeutics in T-cell acute lymphoblastic leukaemia.
Identifying novel therapeutics in chemoresistant breast cancer:
We screened over 30,000 small molecules to find novel therapeutics that kill chemoresistant triple negative breast cancer but that do not kill normal cells. Currently, we are using advanced proteomic approaches to determine mechanisms of action of the novel compounds.
Targeted therapeutics for the treatment of Invasive Lobular Carcinoma:
We are assessing the role of bromodomain proteins as a potential therapeutic target for invasive lobular carcinoma in collaboration with Dr. Darran O’Connor (RCSI). Pictured are Invasive Lobular Carcinoma cells grown in 3D and stained with a viability dye.
We are exceptionally thankful for our funding support: